Jaguar Animal Health will host a Treatment Forum for Veterinarians on Chemotherapy-Induced Diarrhea (DIC) in Dogs on Sunday, January 16 at the Veterinary Meeting & Expo (VMX) in Orlando, Florida
- Canalevia™-CA1, which received conditional FDA approval on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of FDA approval
- US veterinarians, veterinary oncologists and members of the media can click here to register for the CID Treatment Forum; Remote access will be available for participants unable to attend in person
SAN FRANCISCO, CA/ACCESSWIRE/January 12, 2022/ Jaguar Health, Inc. (NASDAQ: JAGX), under its trade name Jaguar Animal Health for the veterinary market, today announced that the company is hosting a Treatment Forum for Veterinarians on Chemotherapy-Induced Diarrhea (DIC) in Dogs on Sunday 16 January from 6 p.m. to 8 p.m. Eastern at the Veterinary Meeting & Expo (VMX) conference in Orlando, Florida.
Renowned veterinary oncologist Dr. Craig A. Clifford, DVM, MS, DACVIM will lead the discussion on the significant burden of chemotherapy-induced diarrhea, share his experience in treating dogs with DIC, and characterize the clinical profile of Canalevia-CA1 , the company’s herbal prescription drug for the treatment of DIC in dogs. Remote access to the event will be available to registered veterinarians and members of the media who are unable to attend the CID Treatment Forum in person. Lunch will be offered to participants attending in person.
CID Treatment Forum Participation Details:
- Date and time of the event: Sunday, January 16, 2022, 6:00 p.m. to 8:00 p.m. Eastern Time
- Location of the event: Lounge 16 at the Rosen Center Hotel, which is adjacent to the Orange County Convention Center (VMX’s location)
- How to register: US veterinarians, veterinary oncologists and members of the media can register on Canalevia.com for the CID Treatment Forum by clicking here
- Remote access: Live remote access to the event will be available to registered US veterinarians and members of the media who are unable to attend the CID Treatment Forum in person.
As part of the launch of Canalevia-CA1, the company is showcasing the product at its exhibit booth at VMX, taking place January 15-19, 2022, at the Orange County Convention Center in Orlando, Florida. Canalevia-CA1 is marketed as a prescription drug under the company’s trade name Jaguar Animal Health. Jaguar Animal Health will be exhibiting at VMX stand number 4610.
Additional information about VMX, the US veterinary industry’s largest annual educational event, is available on the conference website by clicking here.
About Chemotherapy Induced Diarrhea (DIC) in Dogs
Due to the increasing number of chemotherapeutic agents adopted by veterinarians and veterinary oncologists, chemotherapy is rapidly becoming the most widely used cancer treatment in veterinary medicine. Studies have shown that the incidence of DIC is one of the three most common side effects in dogs undergoing cancer treatment1, and managing side effects such as diarrhea can be important in maintaining the success of cancer treatment. More than half of US veterinarians who responded to a recent Jaguar-sponsored survey reported that DIC interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of DIC. .
Crofelemer is a new herbal oral medicine extracted and purified from the sap of the red bark, also called “dragon’s blood”, of the medicinal plant Croton lechleri tree in the Amazon rainforest. Jaguar Health’s wholly-owned subsidiary, Napo Pharmaceuticals, has implemented a sustainable harvest program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity and support. to indigenous communities. Additionally, crofelemer is the active ingredient of an FDA-approved antidiarrheal under botanical guidance indicated for the symptomatic relief of noninfectious diarrhea in adult human HIV/AIDS patients on antiretroviral therapy.
Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only herbal oral prescription product conditionally approved by the FDA to treat chemotherapy-induced diarrhea (DIC) in dogs. Canalevia-CA1 is a canine specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows the product to be marketed while Jaguar continues to gather the substantial evidence of efficacy required for full approval. Jaguar has received Minor Use Designation in a Major Species (MUMS) from the FDA for Canalevia-CA1 to treat DIC in dogs. The FDA has established a “small number” threshold for minor use in each of the seven major species covered by MUMS. The small number threshold is currently 70,000 for dogs, which is the highest number of dogs that can be affected by a disease or condition in a year and whose use still qualifies as use minor.
Important safety information about Canalevia-CA1
For oral use in dogs only. Do not use in humans. Keep Canalevia™-CA1 (crofelemer delayed-release tablets) in a safe place, out of the reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs with known hypersensitivity to crofelemer. Before using Canalevia-CA1, exclude infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common side effects included decreased appetite, decreased activity, dehydration, abdominal pain and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of federal law to use this product other than as directed on the label. Conditionally approved by the FDA pending full demonstration of efficacy under application number 141-552.
About Jaguar Health, Inc., Jaguar Animal Health, Napo Pharmaceuticals, Inc. and Napo Therapeutics SpA
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing novel herbal, non-opioid, and sustainably-derived prescription medications for people and animals suffering from gastrointestinal distress, particularly chronic and debilitating diarrhoea. Jaguar Animal Health is a trading name of Jaguar Health. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of proprietary plant-based human gastrointestinal pharmaceuticals from plants responsibly harvested from rainforest areas. Napo Therapeutics SpA, the majority-owned Italian subsidiary of Napo Pharmaceuticals, is focused on expanding access to crofelemers in Europe.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit www.napotherapeutics.com.
Certain statements contained in this press release constitute “forward-looking statements”. These include statements regarding Jaguar’s expectation to attend the VMX 2022 conference and the expectation that the company will host a CID processing forum on January 16, 2022 during VMX. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “aim”, “anticipate”, ” could”, “intend”, “target”, “project”, “consider”, “believe”, “estimate”, “predict”, “potential”, or “continue” or the negative form of these terms or other similar expressions. The forward-looking statements contained in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections regarding future events. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Some of the factors that could affect our actual results are included in periodic reports on form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does not intend to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise. .
1Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after administration of vincristine or cyclophosphamide with or without maropitant in dogs: a prospective randomized controlled study. J Little animation practice. 2014;55:391-398
Jaguar Health, Inc.
Jaguar – JAGX
THE SOURCE: Jaguar Health, Inc.
See the source version on accesswire.com: